00:11 , Mar 10, 2017 |  BC Innovations  |  Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
01:30 , Mar 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma Cell culture and mouse studies suggest allosteric inhibition of the EED subunit of PRC2 could help treat lymphoma. Screening of small molecule libraries in...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate

Drug platforms TECHNOLOGY: Structural analyses Structural analyses of PRC2 bound to an inhibitor or histone H3 substrate could help guide the development of PRC2 inhibitors for cancer that bypass known mechanisms of resistance. Analysis of...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Enhancer of zeste homolog 2 (EZH2); embryonic ectoderm development (EED) In vitro studies suggest inhibiting EZH2-EED interactions could help treat...
08:00 , Jan 23, 2012 |  BioCentury  |  Emerging Company Profile

RaNA: Specific in epigenetics

Most epigenetics companies aim to globally inhibit regulatory proteins, such as histone methyltransferases or histone demethylases, which may affect thousands of genes. RaNA Therapeutics Inc. is instead targeting long non-coding RNA, or lncRNA, to up-regulate...